Catalysts for Sandoz Inc
291 tracked
Aug 9, 2024
approval
ENZEEVU (AFLIBERCEPT-ABZV) — FDA approval
aflibercept biosimilar
→
Jul 16, 2024
approval
GABAPENTIN — FDA approval
GABAPENTIN
→
Jul 16, 2024
approval
GABAPENTIN — FDA approval
GABAPENTIN
→
Jul 16, 2024
approval
GABAPENTIN — FDA approval
GABAPENTIN
→
Jul 16, 2024
approval
GABAPENTIN — FDA approval
GABAPENTIN
→
Jul 16, 2024
approval
GABAPENTIN — FDA approval
GABAPENTIN
→
Jun 26, 2024
approval
ONDANSETRON — FDA approval
Sandoz Inc
→
Jun 26, 2024
approval
ONDANSETRON — FDA approval
Sandoz Inc
→
Jun 24, 2024
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Jun 12, 2024
approval
HYRIMOZ (ADALIMUMAB-ADAZ) — FDA approval
HYRIMOZ
→
May 31, 2024
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
May 31, 2024
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
May 7, 2024
approval
BUPROPION HYDROCHLORIDE — FDA approval
BUPROPION HYDROCHLORIDE
→
Apr 5, 2024
approval
HYRIMOZ (ADALIMUMAB-ADAZ) — FDA approval
HYRIMOZ
→
Mar 19, 2024
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Mar 19, 2024
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Mar 5, 2024
approval
JUBBONTI (DENOSUMAB-BBDZ) — FDA approval
JUBBONTI
→
Oct 30, 2023
approval
ONDANSETRON — FDA approval
Sandoz Inc
→
Oct 23, 2023
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Oct 13, 2023
approval
AZSTARYS (DEXMETHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Sandoz Inc
→
Oct 13, 2023
approval
AZSTARYS (DEXMETHYLPHENIDATE HYDROCHLORIDE) — FDA approval
Sandoz Inc
→
Oct 13, 2023
approval
RITALIN LA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
RITALIN LA
→
Oct 13, 2023
approval
RITALIN LA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approval
RITALIN LA
→
Oct 13, 2023
approval
FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE) — FDA approval
dexmethylphenidate hydrochloride ER
→
Oct 13, 2023
approval
FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE) — FDA approval
dexmethylphenidate hydrochloride ER
→
Sep 8, 2023
approval
HYRIMOZ (ADALIMUMAB-ADAZ) — FDA approval
HYRIMOZ
→
Aug 24, 2023
approval
TYRUKO (NATALIZUMAB-SZTN) — FDA approval
natalizumab biosimilar
→
Jul 5, 2023
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
May 8, 2023
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Apr 21, 2023
approval
PEMETREXED DISODIUM — FDA approval
Alimta
→